Equities research analysts expect that Mesoblast limited (NASDAQ:MESO) will announce earnings of ($0.25) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Mesoblast’s earnings, with the lowest EPS estimate coming in at ($0.27) and the highest estimate coming in at ($0.23). Mesoblast posted earnings per share of ($0.10) during the same quarter last year, which indicates a negative year over year growth rate of 150%. The firm is expected to issue its next quarterly earnings report on Tuesday, February 26th.

According to Zacks, analysts expect that Mesoblast will report full year earnings of ($0.97) per share for the current fiscal year, with EPS estimates ranging from ($1.03) to ($0.90). For the next fiscal year, analysts expect that the business will post earnings of ($0.87) per share, with EPS estimates ranging from ($1.09) to ($0.65). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Mesoblast.

Mesoblast (NASDAQ:MESO) last announced its quarterly earnings data on Thursday, November 15th. The company reported ($0.20) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.04. Mesoblast had a negative net margin of 171.79% and a negative return on equity of 12.90%. The firm had revenue of $11.64 million during the quarter, compared to analysts’ expectations of $1.03 million.

Several analysts have weighed in on the stock. HC Wainwright set a $17.00 target price on shares of Mesoblast and gave the company a “buy” rating in a research note on Thursday, October 25th. Maxim Group restated a “buy” rating and issued a $16.00 target price on shares of Mesoblast in a research note on Friday, October 12th. ValuEngine upgraded Mesoblast from a “hold” rating to a “buy” rating in a research note on Wednesday, September 26th. Cantor Fitzgerald set a $23.00 target price on Mesoblast and gave the company a “buy” rating in a research note on Sunday, November 11th. Finally, Zacks Investment Research upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research note on Wednesday, September 19th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $13.96.

Shares of NASDAQ MESO traded up $0.16 during midday trading on Friday, hitting $4.78. The company had a trading volume of 16,200 shares, compared to its average volume of 40,438. The company has a quick ratio of 3.57, a current ratio of 3.57 and a debt-to-equity ratio of 0.12. Mesoblast has a twelve month low of $3.35 and a twelve month high of $8.78. The stock has a market capitalization of $459.55 million, a price-to-earnings ratio of -7.59 and a beta of 1.80.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Capital World Investors acquired a new position in shares of Mesoblast during the 3rd quarter worth approximately $3,695,000. Renaissance Technologies LLC increased its position in shares of Mesoblast by 249.8% during the 3rd quarter. Renaissance Technologies LLC now owns 165,161 shares of the company’s stock worth $1,348,000 after purchasing an additional 117,951 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Mesoblast during the 3rd quarter worth approximately $215,000. Finally, Jane Street Group LLC acquired a new position in shares of Mesoblast during the 3rd quarter worth approximately $117,000. Hedge funds and other institutional investors own 3.00% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Featured Story: Short Selling

Get a free copy of the Zacks research report on Mesoblast (MESO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.